Can-Fite BioPharma (NYSE:CANF) Upgraded at D. Boral Capital

D. Boral Capital upgraded shares of Can-Fite BioPharma (NYSE:CANF) from a hold rating to a buy rating in a research report sent to investors on Wednesday, Marketbeat Ratings reports.

Separately, HC Wainwright set a $5.00 target price on shares of Can-Fite BioPharma and gave the company a “buy” rating in a research report on Tuesday. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Can-Fite BioPharma presently has a consensus rating of “Moderate Buy” and an average price target of $42.50.

Can-Fite BioPharma Trading Down 3.7%

Shares of CANF stock opened at $3.36 on Wednesday. Can-Fite BioPharma has a 12-month low of $2.83 and a 12-month high of $23.40. The firm’s 50 day moving average is $3.30 and its 200 day moving average is $4.74. The stock has a market capitalization of $2.20 million, a P/E ratio of -1.88 and a beta of 1.09.

Hedge Funds Weigh In On Can-Fite BioPharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC bought a new position in shares of Can-Fite BioPharma during the fourth quarter worth $41,000. Rhumbline Advisers boosted its position in shares of Can-Fite BioPharma by 42.4% during the first quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock worth $57,000 after acquiring an additional 11,388 shares during the last quarter. Finally, Sabby Management LLC boosted its position in shares of Can-Fite BioPharma by 80.3% during the third quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock worth $871,000 after acquiring an additional 626,306 shares during the last quarter. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).